News | Biogen

September 1, 2021

Biogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Cambridge, MA.— Biogen Inc. (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley 19th Annual Global Healthcare Conference. The webcast will be live on Thursday, September 9, at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section

August 2, 2021

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

List View Grid View

July 21, 2020

Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer

CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. McDonnell joins Biogen from IQVIA™ (NYSE: IQV), where he is Executive Vice

July 21, 2020

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)

In the long-term follow-up study of Zolgensma ® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA 1,2,3 The RESPOND study aims to evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical

July 13, 2020

Initiation of New Phase III Clinical Study (AHEAD 3-45) of BAN2401 Preclinical (Asymptomatic) Alzheimer’s Disease

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced ... edit content here ---- Edit content here -----To access the live webcast, please go to the investors section of Biogen’s website at http://investors.biogen.com/ . Following the live webcast, an archived version of the call will be

July 8, 2020

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

Tofersen is an investigational molecule for superoxide dismutase 1 ( SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative disease Final Phase 1/2 study results demonstrated proof-of-concept and proof-of-biology of tofersen, which is

July 8, 2020

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease

If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, July 08, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the

July 7, 2020

Biogen to Report Second Quarter 2020 Financial Results July 22, 2020

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2020 financial results Wednesday, July 22, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

June 16, 2020

Biogen to Participate in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Chris Henderson, Ph.D., SVP, Head of Research, will participate in a live Q&A in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum. The webcast will be live on Tuesday, June 23, at 12:30 p.m. ET.

June 10, 2020

New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment

After up to 4.8 years of continuous treatment with SPINRAZA, 100 percent of children treated pre-symptomatically were alive, and none require permanent ventilation Patients continued to maintain and make progressive gains in motor function compared to the natural history of the disease, with 96

June 4, 2020

Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020

Full analysis of the CLE part of the LILAC study reinforces positive top-line results; participants who received BIIB059 (anti-BDCA2) demonstrated statistically significant reduction of disease activity compared to those who received placebo Safety and tolerability data further support the

May 28, 2020

Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis Four hundred students from Massachusetts and North Carolina are enrolling in this no-fee program